← back to search

Björn Eliasson

Sahlgrenska University Hospital · SE
Area of research
Endocrinology, Diabetes and Metabolism · Genetics
Research interest
Research interests include Diabetes Treatment and Management, Diabetes Management and Research, Diabetes, Cardiovascular Risks, and Lipoproteins, and Diabetes and associated disorders.
h-index
75
citations
22,817
works
439
NIH funding
primary concept
Medicine
email

Recent publications

Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes
Diabetologia 2025cited by 13position: middledoi
Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study
BMJ 2024cited by 101position: middledoi
GLP-1 Receptor Agonist Use and Risk of Suicide Death
JAMA Internal Medicine 2024cited by 82position: middledoi
Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus
Journal of the American College of Cardiology 2024cited by 21position: middledoi
Testing and Visualization of Associations in Three-Way Contingency Tables: A Study of the Gender Gap in Patients with Type 1 Diabetes and Cardiovascular Complications
Mathematics 2024cited by 1position: middledoi
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study
Hepatology 2023cited by 45position: middledoi
Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study
Clinical Gastroenterology and Hepatology 2023cited by 27position: middledoi
Use of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes
European Journal of Preventive Cardiology 2022cited by 34position: middledoi
Estimating individual lifetime risk of incident cardiovascular events in adults with Type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2)
European Journal of Preventive Cardiology 2022cited by 18position: middledoi
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Diabetes & Endocrinology 2021cited by 176position: middledoi
Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study
Cardiovascular Diabetology 2021cited by 172position: middledoi
Glycemic Control and Risk of Sepsis and Subsequent Mortality in Type 2 Diabetes
Diabetes Care 2021cited by 40position: middledoi
Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study
Diabetologia 2021cited by 30position: middledoi
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
BMJ 2020cited by 101position: middledoi
Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study
Diabetes Care 2020cited by 73position: middledoi
A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes
Diabetes Care 2020cited by 33position: middledoi
Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
BMJ 2019cited by 100position: middledoi
Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study
Diabetes Therapy 2019cited by 65position: middledoi
Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes
Clinical Gastroenterology and Hepatology 2019cited by 63position: middledoi
Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis
Diabetes Care 2018cited by 147position: middledoi
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
The Lancet Diabetes & Endocrinology 2018cited by 71position: middledoi
Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes
Diabetes Obesity and Metabolism 2017cited by 208position: middledoi
Recent trends in life expectancy for people with type 1 diabetes in Sweden
Diabetologia 2016cited by 106position: middledoi
Long-Term Prognosis in Patients With Type 1 and 2 Diabetes Mellitus After Coronary Artery Bypass Grafting
Journal of the American College of Cardiology 2015cited by 75position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Björn Pasternak · Statens Serum Institut11 papers (2018–2025)Peter Ueda · Karolinska Institutet11 papers (2018–2025)Ann‐Marie Svensson · University of Gothenburg10 papers (2015–2021)Mads Melbye · Stanford University9 papers (2018–2024)Soffia Guðbjörnsdóttir · Centre of Registers Vastra Gotaland9 papers (2018–2024)Henrik Svanström · Statens Serum Institut9 papers (2018–2024)Viktor Wintzell · Karolinska Institutet8 papers (2019–2024)Christian Jonasson · Norwegian University of Science and Technology8 papers (2018–2024)Stefan Franzén · AstraZeneca (Italy)7 papers (2018–2021)Kristian Hveem · King's College London7 papers (2018–2023)Thomas Nyström · Karolinska Institutet4 papers (2015–2024) · 4 papers (2023–2024)Mikael Andersson · Statens Serum Institut2 papers (2021–2024)Ann–Marie Svensson · The University of Texas Southwestern Medical Center2 papers (2016–2020)Jonas Söderling · Karolinska Institutet2 papers (2023–2024)Martin J. Holzmann · Karolinska University Hospital2 papers (2015–2017)Andrew Palmer · Primary Health Care2 papers (2016–2020)Marcus Lind · University of Stirling2 papers (2021–2021)Ulrik Sartipy · Karolinska University Hospital2 papers (2015–2017)Carl-Emil Lim · Karolinska Institutet2 papers (2022–2025)